Resident Evil 3 remake game director Kiyohiko Sakata had an interesting new interview with the PlayStation Blog. He revealed why the team gave Nemesis the ability to infect zombies with parasites. Sakata said:
We inevitably decided on this final ability due to the presence of Ganado in Resident Evil 4.
Ganado are humanoid enemies that are created through being infected with the Plagas parasite, the original basis for NE-α.
This makes enemies with NE-α look a lot like Plagas-infected Ganados so that fans can “piece together how Nemesis fits within the whole Resident Evil franchise.”
Many have taken this as a suggestion that Capcom is planning a Resident Evil 4 remake. In Resident Evil 4, Plagas is being researched by the Umbrella Corporation, but if NE-α came from Plagas, that means that Plagas came first.
But there’s more.
In a press release published in April, Capcom confirmed that the Resident Evil 3 remake had shipped two million copies five days after release. The remake of the second game, which was released in 2019, has sold 6.6 million units. The remakes are hugely successful, and it seems unlikely that Capcom would overlook that.
Last month, there was also a report by Video Games Chronicle that revealed that the Resident Evil 4 remake is in development. Sources claimed that Capcom is planning to release the game in 2022.
Capcom has not officially confirmed its plans for these remakes, but it’ss possible that it’s doing this to set a new series canon. With the Resident Evil 3 remake, the company controversially chose to remove the multiple endings that were available in the first release. Removing these endings and making one canon ending may have been part of this plan.
This would make the series easier to understand for new fans. It could also allow Capcom to do new, unexpected things with the series. They could focus on underused characters or stories that were only a small part of the games before.
Either way, it’s an exciting time to be a Resident Evil fan.
Disclaimer: The opinions expressed in this article do not necessarily reflect the views of CCN.com.